Acquisitions and divestitures can be difficult enough for a life sciences Regulatory affairs function. Why make the task more challenging by putting millions of dollars of impacted product revenue at risk?
This post first appeared on Genpact Blogs : Read Genpact Latest Blog Post Online, please read the originial post: here
